Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jason Bacharach, Iqbal Ike K Ahmed, Elizabeth D Sharpe, Michael S Korenfeld, Steven Zhang & Christophe Baudouin. (2023) Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clinical Ophthalmology 17, pages 2575-2588.
Read now
Read now
Stylianos Kandarakis, Alexandros P. Papadopoulos, Georgios Roussopoulos, Eustathios Georgopoulos, Youngsik Chung, Leonidas Doumazos, Areum Baek, Nefeli Ioanna Paizi, Hyunik Shin & Pantelis A. Papadopoulos. (2023) COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Expert Opinion on Drug Safety 0:0, pages 1-12.
Read now
Read now
Christina Scelfo, Reem H. ElSheikh, Muhammad M. Shamim, Javaneh Abbasian, Alireza Ghaffarieh & Abdelrahman M. Elhusseiny. (2023) Ocular Surface Disease in Glaucoma Patients. Current Eye Research 48:3, pages 219-230.
Read now
Read now
Carl Erb, Ingeborg Stalmans, Milko Iliev & Francisco José Muñoz-Negrete. (2021) Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost. Clinical Ophthalmology 15, pages 931-938.
Read now
Read now
Ingeborg Stalmans, Hans Lemij, Jonathan Clarke & Christophe Baudouin. (2020) Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments. Clinical Ophthalmology 14, pages 3675-3680.
Read now
Read now
Articles from other publishers (15)
Philippe DaullJean-Sébastien Garrigue, Hong LiangChristophe Baudouin. (2023) Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review. Journal of Ocular Pharmacology and Therapeutics 39:4, pages 240-251.
Crossref
Crossref
Damian Jaworski, Agata Cieślińska-Rypolc, Katarzyna Jadczyk-Sorek, Iwona Jaworowska-Cieślińska, Beata Bubała-Stachowicz, Ewa Mrukwa-Kominek & Bartłomiej J Kałużny. (2023) Cationic nanoemulsion vs. 0.15% sodium hyaluronate artificial tears in the healing process following modern surface keratorefractive surgery. European Journal of Ophthalmology, pages 112067212311695.
Crossref
Crossref
Anne Hedengran & Miriam Kolko. (2023) Controversial preservation of eye drops: the toxicity of benzalkonium chloride. Adverse Drug Reaction Bulletin 338:1, pages 1311-1314.
Crossref
Crossref
Nupur Vasdev, Nakshatra Chaudhari, Suryanarayana Polaka, Kuldeep Rajpoot, Piyush Gondaliya, Adil Ali Sayyed, Pinaki Sengupta & Rakesh Kumar Tekade. (2023) Current progress in preservative-free topical ophthalmic formulations. Journal of Drug Delivery Science and Technology 79, pages 103996.
Crossref
Crossref
Phatsawee Jansook & Thorsteinn Loftsson. (2022) Aqueous Prostaglandin Eye Drop Formulations. Pharmaceutics 14:10, pages 2142.
Crossref
Crossref
Fredrik Fineide, Neil Lagali, Muhammed Yasin Adil, Reiko Arita, Miriam Kolko, Jelle Vehof & Tor P. Utheim. (2022) Topical glaucoma medications – Clinical implications for the ocular surface. The Ocular Surface 26, pages 19-49.
Crossref
Crossref
Bridgitte Shen Lee, Ranjan Malhotra, Kenneth Sall, Brittany Mitchell & James Peace. (2022) Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension. Clinical Ophthalmology Volume 16, pages 2285-2293.
Crossref
Crossref
Michael H. Goldstein, Fabiana Q. Silva, Nysha Blender, Trung Tran & Srilatha Vantipalli. (2021) Ocular benzalkonium chloride exposure: problems and solutions. Eye 36:2, pages 361-368.
Crossref
Crossref
Olivia Müllertz, Anne Hedengran, Zaynab Ahmad Mouhammad, Josefine Freiberg, Richárd Nagymihály, Jette Jacobsen, Susan Weng Larsen, Jeffrey Bair, Tor P Utheim, Darlene A Dartt, Steffen Heegaard, Goran Petrovski & Miriam Kolko. (2021) Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops. BMJ Open Ophthalmology 6:1, pages e000892.
Crossref
Crossref
T. N. Malishevskaya, S. Yu. Petrov, S. M. Kosakyan & S. A. Vlasova. (2021) When is preservative-free therapy of glaucoma needed and advisable?. Russian Ophthalmological Journal 14:3, pages 25-31.
Crossref
Crossref
Paul Harasymowycz, Cindy Hutnik, Jean-François Rouland, Francisco J. Muñoz Negrete, Mario A. Economou, Philippe Denis & Christophe Baudouin. (2021) Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis. Advances in Therapy 38:6, pages 3019-3031.
Crossref
Crossref
Chloé Chamard, Sophie Larrieu, Christophe Baudouin, Alain Bron, Max Villain & Vincent Daien. (2020) Preservative‐free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008‐2016. Acta Ophthalmologica 98:7.
Crossref
Crossref
O. N. Onufriichuk, I. R. Gazizova, A. V. Kuroyedov & A. V. Seleznev. (2020) The effect of the main active substances of antihypertensive eye drops on condition of the eyes of glaucoma patients. Pacific Medical Journal:3, pages 5-10.
Crossref
Crossref
Yong Woo KimSeung Chan LeeSeoyoung WyEunoo Bak. (2020) Efficacy and Patient Tolerability of Preservative-free Latanoprost in Korean Primary Open Angle Glaucoma Patients. Journal of the Korean Glaucoma Society 9:1, pages 10.
Crossref
Crossref
V. V. Neroev, A. V. Zolotarev, E. V. Karlova, O. A. Kiseleva, M. M. Shishkin & V. N. Germanova. (2019) Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting. Vestnik oftal'mologii 135:6, pages 42.
Crossref
Crossref